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Abstract
Background: Bona fide psychotherapy approaches are effective treatments for generalized anxiety disorder (GAD)
compared to no-treatment conditions. Treatment manuals and protocols allow a relatively high degree of freedom
for the way therapists implement these overall treatment packages and there is a systematic lack of knowledge on
how therapists should customize these treatments. The present study experimentally examines two implementation
strategies of customizing a bona fide psychotherapy approach based on a 16 session time-limited cognitive-behavioral
therapy (CBT) protocol and their relation to the post-session and ultimate treatment outcomes.
Methods: This trial contrasts two different implementation strategies of how to customize the in-session structure of
a manual-based CBT-protocol for GAD. The patients will be randomly assigned to two implementation conditions: (1) a
systematic focus on subtle changes lasting from 7 to 20 min at the check-in phase of every psychotherapy session and
(2) a state-of-the-art (SOTA) check-in phase lasting several minutes mainly focused on the session goals. Potential therapist
effects will be examined based on an ABAB crossed-therapist design. Treatment outcomes will be assessed at the following
times: post-session outcomes, treatment outcome at post assessment and 6- as well as 12-month follow-up.
Discussion: The proposed randomized clinical implementation trial addresses the clinically relevant question of how to
customize a bona fide psychotherapy protocol experimentally contrasting two implementation strategies. Through the
development and testing of the proposed implementation design, this trial has the potential to inform therapists about
efficacious implementation strategies of how to customize a manual-based treatment protocol in respect to the timing
of the in-session structure.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT03079336) at March 14, 2017.
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Background
Personalized medicine refers to several efforts of tailoring
interventions to the characteristics of each individual
patient (e.g. [1, 2]). For psychotherapy, one can argue, that
personalization of treatments is already part of the clinical
reality of most practitioners (e.g. [3, 4]). However,
evidence-based guidelines of how to customize treatments
and how to more specifically structure the sessions are
largely missing. This might in part be due to the fact that
in psychotherapy and in human treatments more gener-
ally, not only does patient heterogeneity need to be taken
into account, but potentially also that of the therapist and
their collaborative qualities between each other.
Within the over 25,000 hits in relevant data bases during
the past 5 years referring to randomized controlled trial de-
sign in human interventions, based on a search at February
2018 in Medline, PsychINFO and ERIC, there is a lack of
sensitivity to heterogeneity in therapists’ effectiveness (i.e.
therapist effects) and a lack of systematized knowledge
about how therapists implement their treatments [5]. There
is a need for further work developing and testing study
designs that investigate therapist effectiveness and related
therapists’ implementation strategies [6–9].
The present study design represents an important step
toward addressing this gap by investigating two imple-
mentation strategies along therapist and patient variability
with a bona fide psychotherapy approach for individuals
that suffer from generalized anxiety disorder (GAD). We
are conducting a novel two-arms, patient blinded, ABAB
crossed-therapist randomized controlled implementation
trial design.
Therapist effects in randomized clinical trials
Blinded allocation of patients and health professionals is
an important claim in double-blind randomized pharma-
ceutical trials. It is a well-known consideration for the
identification of a true treatment effect and for avoiding
potential confounding effects from patients and health
professionals. In evidence-based human interventions,
health professionals can not be blinded, because hope-
fully they are well-informed and fully aware of the inter-
ventions that they apply (e.g. the professionals apply a
specified surgery, educational program, or psychological
intervention). Such conditions are common in human
interventions of evidence-based medicine [10], nursing
[11], social work [12], education [13], and psychological
interventions more generally [5, 14].
There are at least three positions regarding the debate
about non-blinded therapist conditions and how to handle
potential therapist effects in human interventions: (1)
advocates for double-blind trial designs highlight general
biases of non-blinded allocations, assuming that blinded
conditions may help to eliminate potential confounding
effects (e.g. [15]), (2) advocates of evidence-based human
interventions often emphasize uniformity of evidence-
based treatments without considering therapist effects as
a potential confounder, i. e. potential therapist effects
often are neglect at the analyses and discussion sections
when conducting study designs where patients are nested
in therapists (see [16]), and (3) a third way to investigate
therapist effects either in non-blinded as well as blinded
conditions lies in the direct investigation of these potential
effects and the development of study designs that allow
for the estimation of such effects; i.e. therapist effects con-
sidered as true effects rather than biases or confounders
(see [5, 17]).
Crossed-therapist designs were proposed for naturalis-
tic intervention studies [18, 19], where each therapist is
allocated into two or more treatment conditions, and
therefore potential differences in overall therapist effect-
iveness can be estimated across conditions. However, the
therapists’ individual treatment preferences for a certain
condition may impact her effectiveness across condi-
tions, and thus, therapist preferences should be explicitly
assessed in such designs [5, 19].
Generalized anxiety disorder
Randomized controlled trials usually are focused on one
particular patient population (e.g. by specifying disorders or
particular contexts of suffering) to reduce the patient vari-
ability and to enhance the precision of research results.
Uncontrollable worry is a primary symptom of GAD and
constitutes a maladaptive cognitive strategy to avoid the ex-
perience of anxiety [20] and other emotional states [21, 22].
Individuals who suffer from GAD show deficits in detecting
and regulating emotional states, which might accelerate a
positive feedback circuit between general stress symptoms
and pathological worrying (e.g. [23]). Experiential avoidance
might lead to a restriction in proactive behaviors because
individuals become focused on preventing negative events
and maintaining safety [24], rather than on pursuing activ-
ities that are consistent with their personal values (e.g.
[25]), which might impact the content of psychotherapy
sessions [26].
Empirical evidence of bona fide psychotherapy
approaches for GAD
There is meta-analytic evidence that psychotherapy condi-
tions conducted by trained professionals that are designed
to be fully therapeutic (bona fide psychotherapy; [5, 27]) are
more effective treatments compared to no-treatment and
treatment as usual for individuals with GAD [28–30] as well
as for individuals who suffer from anxiety and depression
comorbidities more generally [27, 31]. For cognitive-
behavioral therapy (CBT), there are a number of GAD-
specific interventions, such as GAD-psychoeducation,
applied relaxation, restructuring of (meta-) cognitions, (im-
agery-) exposure, and in vivo confrontation, that primarily
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reference standard techniques to reduce and compensate
GAD symptoms (e.g. [32–39]; but also [40]). In daily
practice, however, it is a well-known fact that patients and
therapists usually are not uniformly skilled. On a broader
perspective psychotherapy dialogues were observed to be
highly collaborative and responsive treatments, through
which therapists as well as patients work together to achieve
well-specified treatment goals that consider the patients’
entire living environment [41–44].
Therapist’s responsiveness to subtle patient changes
It is a robust finding in psychotherapeutic as well as
pharmacological mental health treatments that sudden pa-
tient’ changes commonly occur independently of the intake
severity. For example, sudden symptom changes (sudden
gains) occur in approximately 20–40% of all clients, up to
60–80% in those who benefit from treatment in general
[45–49], and in GAD more specifically [50, 51]. Whereas
such research focuses on sudden symptom reduction of
particular symptoms [52, 53], other investigators highlight
psychological changes involving other aspects of a compre-
hensive definition of health [54] including substantial as
well as more subtle changes in wellbeing and psychosocial
functioning [47, 55–59].
From a therapist’s implementation perspective, detecting
and integrating subtle patient changes, even small and sub-
tle ones, in a more systematic manner might impact the
treatment processes and its outcomes [46, 59]. It is likely
that many therapists already respond to sudden gains and
subtle changes, and in this way, help to regulate the “speed”
of therapeutic change and the consolidation of gains
achieved [47, 60]. Even though subtle changes seem to
occur in many psychotherapies, to the best of our know-
ledge, there is no trial that systematically takes advantage of
such changes using rigorous randomized controlled trial
methodology. There is a need for future research in this
area, especially because subtle changes are apparent in
many mental health conditions [45–47, 57, 59, 61–63].
In a prior three-arm, single-blinded, randomized con-
trolled implementation trial (IMPLEMENT 1.0; [64]) we
recruited 57 adults with GAD to participate in a cognitive
behavioral treatment approach very similar to the approach
used in our current trial. We randomly assigned eligible
patients to three different priming conditions: (1) adherence
priming, in which the peer-priming with the therapist had a
systematized focus on patients’ individual GAD symptoms
and how to compensate for these symptoms within the
manual, (2) resource priming, in which the peer-priming
with the therapist had systematized foci on patients’
strengths and abilities and how these strengths can be capi-
talized within the same package and (3) supportive resource
priming (that additionally allowed the invitation of a sup-
portive person into therapy sessions). The results indicated
that all three priming conditions showed a highly significant
reduction of symptoms over time. However, compared
with the adherence priming condition, both resource
priming conditions indicated faster symptom reduction
during treatment. In contrast to this past trial where the
implementation conditions focused on different peer-
priming strategies, in the present implementation trial we
focus on contrasting two implementation strategies that
focus on taking different approaches to subtle change
made by the patient.
Aims of the implementation trial
Rather than contrasting increasing numbers of new
overall treatment-packages, an additional approach may
be to increase the understanding of fine-grained imple-
mentation strategies within already effective psychother-
apies. Such research questions require the development
of novel randomized clinical implementation designs
that simultaneously investigate potential implementation
effects along with therapist as well as patient effects [5].
This trial investigates two different implementation
strategies of customizing a bona fide psychotherapy based
on a well-introduced CBT-protocol for GAD [39]. The
patients will be randomly assigned to two implementation
conditions: (1) a systematic focus on subtle changes
lasting from 7 to 20 min at the check-in phase of every
psychotherapy session [61, 65]; and (2) a state-of-the-art
(SOTA) check-in phase lasting several minutes mainly
focused on the session goals. Potential therapists’ imple-
mentation effects will be examined based on an ABAB
therapist allocation (see design). The main research ques-
tions are as follows:
(1)Practicability: Is the newly developed randomized
clinical implementation trial design and particularly
the therapists’ ABAB allocation practicable (ABAB
crossed-therapist design), and what are the specific
challenges when conducting such a structured
design at the patient as well as therapist level?
(2)Post-session outcomes: Are there differences in
process evaluations measured by post-session reports
for the two implementation conditions? Furthermore,
are early post-session outcomes predictors of
symptom change and mediators of ultimate therapy
outcome (e.g. [66])?
(3)Treatment outcomes: What are the differences
in the treatment efficacy of the two randomized
implementation conditions, (1) in dropout rates,
(2) in self-reported primary and secondary
outcomes [64]?
(4)Therapist effects: Are the implementation effects
robust across therapists? Is there an interaction
effect between potential therapists’ preferences for
a particular implementation condition and outcome?
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Methods/design
Design
It is a common data structure in human interventions that
patients are nested within therapists. The proposed random-
ized controlled design systematize both levels, i. e. patient as
well as therapist level (Fig. 1 for the nested design):
(1)At patient level: Eighty patients will be allocated
within a traditional 2 × 4 randomized controlled
design with one between-subject factor (systematic
focus on subtle changes vs. SOTA check-in phase)
and one within-subject factor (assessment times:
pre-, intermediates-, post-treatment and follow-ups).
(2)At therapist level: Twenty therapists will each
conduct four therapies using an ABAB-design
randomly starting with a SOTA check-in phase or
a systematic focus on subtle changes (80 patients).
Overall, this ABAB crossed-therapist design allows
us to integrate across what might be considered
single case studies of 20 therapists [67]. An advantage
of this design is, that within-subject effects can be
estimated. However, multiple observations may also
lead to learning effects, and potential carry over effects
may be detected from the therapist’s first to the fourth
therapy. Most importantly, however, such therapist
effects are not considered as effects that have to be
eliminated. Rather, the longitudinal, multilevel design
allows us to estimate therapist effects in parallel to
the implementation effects [5].
Participants
(1)Inclusion/exclusion criteria: Participants will be
included in the study if they: (1) are 18 years or
older; (2) agree to the informed consent, (3) can
speak German; and (4) fulfill the diagnostic criteria
of GAD DSM-5. Participants will be excluded for
the following reasons: (1) they have a score of 2 or
higher on the suicide item of the Beck Depression
Inventory and/or are found to have active suicidal
plans during the diagnostic screening interview, (2)
they are currently taking a psychotic or bipolar
disorder medication, or (3) they are currently
receiving treatment from a professional
psychotherapist. Prescribed medications for anxiety
or depressive disorders do not lead to exclusion
from the study, if the dosage has remained constant
for at least 1 month. The presence of comorbidities
does not result in exclusion from the study, if GAD
is in the foreground according to the severity rating
of the Diagnostic Interview for DSM-diagnoses.
(2)Recruitment: Participants will be recruited by e-mail
distributors of internet forums. Individuals interested
in participating in the study will contact the study
office via SMS, e-mail or phone. Positively screened
patients will be invited for an intake assessment to
determine whether they will be included or excluded
using a standardized diagnostic interview.
Participants that are not screened positively will
be informed of more appropriate treatments via a
phone call or, if requested, a face-to-face contact.
(3)Randomization and treatment allocation. After
meeting the inclusion criteria, patients will be
randomly assigned to one of the two
implementation conditions (systematic focus on
subtle changes or SOTA check-in phase). Treatment
allocation is performed using an online application
for full randomization. The whole randomization
Fig. 1 Randomized, clinical implementation trial design: Patient and therapist allocation
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procedure will be conducted by an independent
person outside of the project implementation. In
this way, we aim to ensure that the trial arms are
fully randomized with respect to the patients’
baseline characteristics. Because all patients will
be treated using the same CBT-manual, patients
are blinded to their treatment allocation and are
not informed about the randomization procedure.
GAD treatment protocol
Modern CBT for GAD typically consists of psychoeduca-
tion, relaxation training and/or mindfulness exercises (RT/
M), cognitive restructuring (CR) and imagery exposure (IE)
as major interventions to address the various GAD-related
problems. The “Mastery of your Anxiety and Worry” man-
ual (MAW-package) is a well-structured, and internation-
ally well-introduced cognitive-behavioral treatment [39, 68].
In the present study, the MAW-package will be applied
within a usual 16-session individual therapy format and up
to three further booster sessions. The treatment protocol
was based on a 16-h workshop presented by one of the co-
developers of the treatment manual. The MAW-package
consists of (1) psychoeducation regarding the nature of
GAD and the rationale for the treatment program (sessions
1 and 2), (2) RT/M (sessions 3 and 4 and portions of
sessions thereafter), (3) CR (sessions 5, 6 and 7 and portions
of sessions thereafter), (4) IE (sessions 8–12), and (5) plans
for maintenance, relapse prevention and termination (ses-
sions 13–16). However, the implementation of an bona fide
treatment is largely principle-based, allowing considerable
therapeutic flexibility in determining and timing of different
treatment aspects.
The session format of 50–60 min usually consists of (1) a
check-in phase of 5 to 10 min that includes patients wel-
coming, reviewing self-help and agenda setting, (2) a work-
ing phase around 35–45 min that focuses on the previously
agreed session goals, (3) a feedback phase of 5 to 10 min
that summarizes the session and includes a negotiation of
the upcoming self-help assignment.
Implementation conditions: In-session structure
The session check-in phase will be systematically varied
by the following two conditions while keeping the overall
session lengths of 50–60 min constant:
(1)State-of-the-art (SOTA) check-in phase: The
therapists will apply the usual SOTA check-in phase
lasting between 5 to 10 min, as recommended in the
preexisting guideline including reviewing progress
in self-help and agenda setting [39]. In this condition
progress, subtle changes and sudden gains may
be an explicit topic and there is no restraint to
talks about topics. However, the therapists are not
obligated to take a systematic focus on potential
subtle changes and they may use the timing of
the sessions to involve the patients into the other
phases of therapy.
(2)Prolonged focus on subtle changes: Based on the
robust findings that over 90% of the patients will
experience subtle changes [69, 70] e.g. apparent
at the pre-session assessments, the therapists will
extend the above-mentioned check-in phase to 7 up
to 20 min in which small and subtle changes are
systematically worked with. These subtle changes
will further be explored by focusing on the following
aspects [61, 71]: (1) the precise change situation, (2)
related emotional states, (3) related helpful thoughts
and self-verbalizations, (4) reinforcement of generalized
self-efficacy and treatment motivation, (5) benefit for
the upcoming session goals. Exploratory video analyses
of GAD patients indicated that the explicit examination
of the patients’ changes and immediate competencies
usually observed at the check-in phase was highly
associated with therapy success [26].
Therapists
Twenty psychologists with a master degree and participat-
ing in post-graduate psychotherapy trainings are recruited
from local psychotherapy-training centers. In addition to
the clinical internships, these systematized 5-year post-
graduate training includes (1) 600 h of weekend work-
shops for psychotherapy interventions in single, couple,
and group settings, (2) 200 h of supervision, and (3) 200 h
of personal therapy. Some of those therapists have experi-
ence as study administrators in a prior randomized
controlled trial for GAD (ClinicalTrials.gov Identifier:
NCT02039193). All therapists will participate in an initial
16-h workshop presented by one of the co-developers of
the treatment manual (Zinbarg) [39]. The therapists will
be regularly supervised in small groups on a bi-weekly
basis. The supervision is conducted in mixed groups for
all conditions. All supervisors also participate in the initial
16-h workshop. For a therapist performing an ABAB
sequence of conditions, the therapy will be performed as
followed: First therapy in the SOTA-check-in phase condi-
tion, second therapy in the prolonged focus on subtle
changes condition, third therapy with the SOTA check-in
phase condition, forth therapy with the prolonged focus
on subtle changes condition (ABAB sequence); the other
half of the therapists will start with the prolonged focus
on subtle changes condition (BABA sequence).
Assessments
For an overview of the assessments see Table 1. At intake,
GAD-diagnosis and its core symptomatology is identified
according to the structured interview section for GAD
(DIPS; [72]). Furthermore, GAD-criteria are assessed using
self-reports. The individual worries are identified using the
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Penn State Worry Questionnaire (PSWQ; [73]) and the
Worry Domain Questionnaire (WDQ; [74, 75]). Mental
disorders on Axis I are assessed using face-to-face diagnos-
tic interviews (Strukturiertes Klinisches Interview für DSM,
SKID-I; [76]).
(1)GAD-specific (primary) outcomes: The Penn
State Worry Questionnaire (PSWQ; [73]) is a
16-item measure of the frequency and intensity
of worry. It has considerable internal consistency
(α = 0.86 in the prior trial). The Beck Anxiety
Inventory (BAI; [77]) is a 21-item measure for
anxiety symptoms (α = 0.92 in the prior trial).
(2)General (secondary) outcomes: The Beck
Depression Inventory II (BDI-II; [78]) is a
21-item measure for depressive symptoms
(α = 0.92 in the prior trial). The 9-item short
version of the Symptom Check List (SCL-9; [79])
is an index for general severity (α = 0.86 in the
prior trial). The short version of the Resource
Self-Report Questionnaire (RES; [80]) measures
various domains of individual and interpersonal
strengths (α = 0.92 in the present sample).
In the prior trial, all GAD and general outcome self-
report assessments were highly correlated (0.74 > r > 0.47)
and a principal component factor analysis extracted one
component that explained 67.5% of the total variance. For
the purposes of the present trial, we therefore intend to
include a standardized composite measure (“outcome
composite”) that takes all the five GAD and general self-
report measures into account (α = 0.73 in the prior trial;
see also [81] for psychotherapy outcome definitions).
(3)Post-session outcomes: The following process
measures are examined: (a) Post-session outcomes
(evaluated by therapists and patients): Working
Alliance Inventory (WAI) [82, 83], Bern Post-Session
Reports (BPSR) [84], and PSWQ patient self-report
symptom status are conducted based on a session-
by-session assessment from session 1 to 16.
Furthermore, patient and therapist outcome
expectations as well as therapist implementation
preferences and in-session focus on subtle change
will be assessed based on self-report items.
(4)Safety outcomes: Suicidal ideation is assessed as
safety outcome in the structured assessment at
Table 1 Assessments
Measures Assessment time
Recr. Pre S-by-S Int. Post FU
Eligibility
Structured Interview for DSM (SCID) +
GAD-diagnosis (DIPS) +
Worry Domains Questionnaire (WDQ) +
GAD-outcomes
Beck Anxiety Inventory (BAI) + + + +
Penn State Worry Questionnaire (PSWQ) + + 1–16 + + +
General-outcomes
Premature termination 1–16 + + +
Beck Depression Inventory (BDI) + + + + +
Brief Symptom Inventory (BSI) + + + +
Resource potential questionnaire (RES) + + + +
Self-report process-measures
Working Alliance Inventory - Patient (WAI-P) 1–16
Working Alliance Inventory – Therapist (WAI-T) 1–16
Bern Post-Session Report – Patient (BPSR-P) 1–16
Bern Post-Session Report – Therapist (BPSR-T) 1–16
Patients’ Therapy Expectation and Evaluation (PATHEV) + +
Therapists’ preferences and outcome expectations + 1
Therapists’ self-reported focus on subtle changes 1–16
1At the beginning of the study, 2 At the end of the study, Recr. Recruitment, Pre Intake assessment, S-by-S Session by session assessment, Int. Intermediate
assessment (at session 5 and 10), Post Post assessment, FU Follow-up assessments (at 6- and 12-months after treatment termination)
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baseline, post, and follow-up measures and if
indicated in every therapy session. As an outcome,
suicidal ideation is assumed when the suicidal
ideation item of the BDI is endorsed with
a value > 1. In this case, individuals will be
immediately contacted by telephone for further
assessment and coordination as well as decisions
for more appropriate treatments will be based
on the general psychotherapeutic guidelines for
suicidal ideation [85].
Statistical analysis
Along more traditional statistical approaches to handle
the nested data structures, Longitudinal Multilevel Model-
ing (MLM) will be used to analyze the (intensive) longitu-
dinal, nested data structures [86–89]. This data-analytical
approach is specifically suitable to analyze the type of data
that will be collected in the proposed implementation
trial. For the primary research questions for post-session
and treatment outcomes, MLM with time as a repeated
within-group factor and implementation condition as a
between-groups factor will be used [90]. A benefit of
MLM, in comparison to traditional ANOVA with repeated
measures lies in the individual parameterization of the
process variables over various levels (repeated measures as
random variables; [89]). The main analyses will be con-
ducted on the intention-to-treat sample and the completer
data. Between-group effect sizes will be based on pre-post
within control Cohen’s dppwc suggested by Carlson and
Schmidt [91] which is a mean difference estimate that
takes into account both intake values at pretreatment and
differences between each treatment condition.
Statistical exemplification
The following analysis estimates the treatment efficacy of
the two implementation conditions using random effects
multilevel models [89]. To consider the variance compo-
nents at each level (assessment times nested in patients
and therapists), we will conduct 3-level models where the
repeated assessments of the primary outcome at level 1
will be nested within patients at level 2 and therapists at
level 3 (for a comparable model see e.g. [92]). Using a
step-by-step approach [91], the growth models potentially
will end up in a multi-predictor model to investigate the
main outcome-predictors at each level simultaneously. An
example of such a model is: At Level 1 (assessment level),
PSWQijk = π0jk + π1jk(time) + eijk
where PSWQijk is the estimated value of the Penn State
Worry Questionnaire (PSWQ) within a time-specific
assessment of each patientj and therapistk; π0jk represents
the intake-centered intercept of the repeated PSWQ-
measures within each patient; π1jk (time) represents the
decrease of symptoms from pretreatment up to post-
treatment, and eij represents the corresponding error term.
At Level 2 (patient level),
for intercept: π0jk = ß00k + ß01k(number of comorbidi-
ties) + r0jk.
for time: π1jk = ß10k + ß11k(implementation condition)
+ r1jk.
where π0jk is the estimate of the true population overall
patients’ intake PSWQ and π1jk is the estimation of the
overall symptom reduction across the repeated assess-
ments. Further, ß00k and ß10k are the estimated overall
grand means of PSWQ intercept and time, and ß01k(num-
ber of comorbidities) and ß11k(implementation condition)
represent the specific patients’ level predictors on inter-
cept π0jk and growth π1jk respectively. Finally, r0jk and r1jk
are the corresponding error terms at the patients’ level.
At Level 3 (therapist level):
ß00k = γ000 + u00k
ß01k = γ010
ß10k = γ100
ß11k = γ110 + γ111(therapists
’ implementation prefer-
ence) + u11k
where ß00k is the estimate of the true population thera-
pists’ overall intake PSWQ and ß10k is the corresponding
overall true population symptom reduction among thera-
pists; ß01k and ß11k are the overall therapists’ true popula-
tion estimations of the level 2 predictors. Furthermore, γ000
and γ100 are the estimated overall grand means of PSWQ
intercept and time at therapists’ level, γ111 (therapists’
implementation preference) is the hypothesized therapists’
preference on the implementation condition ß11k. Finally,
u00k and u11k are the corresponding error terms at the ther-
apist level (see also [6, 93] for a conceptual frame).
The various multi-predictor models will be compared
using Akaike information criterion (AIC) and the Bayesian
information criterion (BIC; see [88]) and deviance test of
variance components respectively [89].
Power considerations
With respect to the differences between the two compara-
tive conditions, based on prior studies with transdiagnostic
disorders [94], social phobia [95], depression [96], and
GAD [64], we planned to demonstrate a medium effect size
of Cohen’s d = 0.40 between the implementation conditions
on the outcome composite. Assuming an α error level of
0.05, a statistical power (1-Beta) of 0.80, and a correlation
of 0.40 between the pre- and post-measurements, the pro-
posed study of 40 participants in each condition treated by
20 therapists is able to detect such an effect size [97].
Discussion
Treatment protocols allow a relatively high degree of
freedom for the way therapists implement the treatment
protocols. The present design is one of the very first tri-
als that experimentally examine the therapists’ sensitivity
to changes and its relation to treatment outcome. More
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specifically, two implementation strategies of session
structuring (SOTA check-in phase, prolonged focus on
subtle changes) are compared to each other in the same
overall treatment package.
The hierarchical structure of the systematized design
allows the simultaneous examination of patients’ and
therapists’ contributions. In contrast to pharmaceutical
trials, therapists and patients are informed and (hope-
fully) proactively involved in the psychotherapeutic treat-
ment. This involvement is not a bias which has to be
eliminated; it might rather be an active ingredient of a
successful psychotherapy in which the therapists and the
patients take a proactive and collaborative role in the
treatment plan [41]. Therefore, the present design allows
to experimentally investigate some potentially meaning-
ful aspects of this responsive proactivity.
Bias minimization
The hierarchical structure of the implementation design
allows a systematic investigation of patients’ as well as the
therapists’ contributions simultaneously; and in one further
implementation aspect, it allows to examine an experimen-
tal contrast (SOTA check-in phase vs. prolonged focus on
subtle changes check-in phase). But for the similarities and
differences of the proposed randomized clinical implemen-
tation trial with the common randomized clinical trial
design see Table 2.
(1)Patients: Patients will be randomly assigned to
conditions to reduce systematic selection biases
in participant characteristics. The inclusion and
exclusion criteria allow for a relatively homogeneous
group of individuals with GAD diagnoses. In
traditional trials, where two or more distinctive
treatment protocols are compared to each other,
patients have to be informed about the various
randomized treatment conditions of the active
treatments (e.g. psychotherapy vs. waiting list).
Therapist will apply the very same bona fide
psychotherapy protocol in both conditions.
Implementation-strategies are part of the therapist
individual case preparation. Based on common
practice, therapists are not obligated to inform
the patient about any specific topic of therapist
case preparation, related supervision, or personalized
implementation strategies. Therefore, implementation
condition can be blinded for the patient at every time
of the study conduction. This is one of the very first
designs that allows for blinded patient conditions
which minimizes some of the potentially major
concerns of the more traditional randomized
controlled trials of psychotherapy and psychological
interventions more generally.
(2)Therapists: A potential bias due to the therapist
preferences is a concern, especially in human
treatments where inductions of outcome
expectations can be impactful for patients as well
as therapists. In the proposed design, potential
therapist effects are not considered as a bias that
has to be eliminated. In contrast, due to the nested
data structure, the present ABAB crossed-therapist
design is able to take into account such possible
effects [6]. Furthermore, this design allows
systematizing potential implementation effects
within therapists.
(3)Researchers: The existence of researcher allegiance
effects is a robust meta-analytic finding in both
comparative (e.g. [98]) and correlative designs
(e.g. [99]). In many randomized controlled trials,
maximally distinctive treatment protocols are
contrasted with each other (e.g. cognitive behavioral
therapy vs. psychodynamic therapies; online vs.
face-to-face treatments, additive components vs.
standard treatment). Imbalances in researcher
allegiance might favor one treatment, sometimes
very explicitly and sometimes more subtly. For
example, some patients might have been attracted
by a specific intervention and therefore self-selected
the specialized clinic, but were randomized in the
alternative treatment. Another example is that
the designed control groups are intended to not
be fully therapeutic [not bona fide, 5]. Even though
we presented some literature of how to innovate
state-of-the-art CBT (what might be an indicator
for researcher allegiance in favor to the prolonged
focus on subtle changes condition), both
Table 2 Similarities and differences of randomized controlled trial and randomized clinical implementation trial designs in human
interventions
Design: Randomized clinical trial Randomized clinical implementation trial
Treatment manual / protocol: Contrast between different packages
(e.g. comparative, additive, subtractive designs)
Same package over all conditions, contrasts between
implementation strategies (e.g. timing, sequence, focus)
Patient allocation: Randomized, not blinded Randomized, blinded
Therapist allocation: Not randomized, not blinded Randomized or systematic allocation (e.g. ABAB), not
blinded
Researcher allegiance: Substantial Not investigated yet
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interventions are designed to be fully therapeutic
within the very same bona fide treatment package.
Therefore, the aim of the present investigation is
not to contrast distinctive treatments packages. The
aim is rather to keep the overall treatment package
constant in order to investigate a relevant clinical
research question of treatment implementation
(i. e. therapist consideration of subtle patient
change) within a treatment package. Nonetheless,
despite the awareness of potential researcher
allegiance effects in our research team, it might
be difficult to fully eliminate such effects over the
course of the lasting study implementation. Hence,
during the publication process we will discuss this
potential limitation cautiously.
To conclude, an essential contribution of this study
will be to better understand successful implementation
strategies of how to customize a manual-based psycho-
therapy in respect to the session timing. In addition, the
present randomized controlled implementation trial may
provides further insights about therapist effects based on
a ABAB crossed-therapist allocation where patients can
be fully blinded about their implementation condition.
Most relevant, the present study protocol may sensitize
for potential implementation effects when conducting
randomized controlled trials in human interventions.
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